Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.53 1.20% 0.03
BCRX closed up 4.6 percent on Tuesday, October 15, 2019, on 75 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Nov 4

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical BCRX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 1.20%
Oversold Stochastic Weakness 1.20%
NR7 Range Contraction 5.86%
Inside Day Range Contraction 5.86%
Wide Bands Range Expansion 5.86%
Oversold Stochastic Weakness 5.86%
Stochastic Buy Signal Bullish 3.48%
Wide Bands Range Expansion 3.48%
Oversold Stochastic Weakness 3.48%
Doji - Bullish? Reversal 5.42%

Older signals for BCRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Chemistry Biotechnology Diseases Chemical Compounds Enzymes Gout Seasonal Influenza Acetamides
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.95
52 Week Low 2.35
Average Volume 1,408,332
200-Day Moving Average 5.6824
50-Day Moving Average 2.8371
20-Day Moving Average 2.7593
10-Day Moving Average 2.531
Average True Range 0.1936
ADX 20.87
+DI 13.1439
-DI 22.9779
Chandelier Exit (Long, 3 ATRs ) 2.7492
Chandelier Exit (Short, 3 ATRs ) 2.9308
Upper Bollinger Band 3.3115
Lower Bollinger Band 2.2071
Percent B (%b) 0.27
BandWidth 40.024644
MACD Line -0.1562
MACD Signal Line -0.1181
MACD Histogram -0.0381
Fundamentals Value
Market Cap 201.07 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -4.03
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.70
Resistance 3 (R3) 2.67 2.59 2.66
Resistance 2 (R2) 2.59 2.54 2.60 2.65
Resistance 1 (R1) 2.54 2.51 2.57 2.57 2.64
Pivot Point 2.46 2.46 2.47 2.47 2.46
Support 1 (S1) 2.41 2.41 2.44 2.44 2.36
Support 2 (S2) 2.33 2.38 2.34 2.35
Support 3 (S3) 2.28 2.33 2.34
Support 4 (S4) 2.31